MLLT10 and acute myeloid leukemia: In a retrospective international study of 1130 pediatric patients with KMT2A-r AML, patients harboring abnormalities in 6q27 (KMT2A::AFDN), 4q21 (KMT2A::AFF1), 10p12 (KMT2A::MLLT10), 10p11.2 (KMT2A::ABI1), and 19p13.3 (KMT2A::MLLT1) were categorized into the high-risk group, with all remaining cases allocated to the non–high-risk group [32].